SCHEMBL1466934

SCHEMBL1466934

NS(=O)(=O)c1c(Oc2ccccc2)cccc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA2 P00918 4/20 0.46
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA7 P43166 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CA4 P22748 1/20 0.45
SOS1 Q07889 1/20 0.45
CA9 Q16790 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ADRA2C P18825 1/20 0.43
TTR P02766 1/20 0.43
ALOX15 P16050 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.42
MITF O75030 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11371039 0.79 ALOX15 (0.57) L3MBTL1CA2CA12CA1CA7
SCHEMBL28078714 0.78 CTNNB1 (0.50) CTNNB1CA2CA12CA1CA7
SCHEMBL10865257 0.78 DPP4 (0.54) CTNNB1L3MBTL1CA2CA12CA1
SCHEMBL1798 0.77 CTNNB1 (0.71) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL1464916 0.77 CTNNB1 (0.61) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL4129945 0.76 CTNNB1 (0.69) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL8496446 0.76 CTNNB1 (0.69) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL11875755 0.76 CTNNB1 (0.69) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1
Bicarbonate SCHEMBL21517637 0.76 CTNNB1 (0.69) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1
Bicarbonate SCHEMBL236889 0.76 CTNNB1 (0.69) CTNNB1L3MBTL1TDP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071197-A1 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS BIOLIPOX AB (LV) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071197-A1 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS LTC4S, LTB4R2, LTB4R CTNNB1 1574/4885L3MBTL1 536/4885TDP1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.